| 6.01 0.08 (1.35%) | 06-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.66 | 1-year : | 8.6 |
| Resists | First : | 6.56 | Second : | 7.36 |
| Pivot price | 5.79  |
|||
| Supports | First : | 5.25 | Second : | 4.36 |
| MAs | MA(5) : | 5.88  |
MA(20) : | 6.01 |
| MA(100) : | 5.69 |
MA(250) : | 6.06 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 45.9 |
D(3) : | 40.7 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 13.5 | Low : | 3.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CLNN ] has closed below upper band by 31.6%. Bollinger Bands are 33% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.05 - 6.07 | 6.07 - 6.09 |
| Low: | 5.77 - 5.8 | 5.8 - 5.82 |
| Close: | 5.96 - 6.01 | 6.01 - 6.05 |
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
Thu, 18 Jun 2026
Clene Inc. (CLNN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Wed, 17 Jun 2026
Clene Inc. (CLNN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tue, 16 Jun 2026
Clene Inc. (CLNN) Institutional Confidence - TradingKey
Mon, 15 Jun 2026
Clene (CLNN) Chief Science Officer receives 45,000-share stock option grant - Stock Titan
Mon, 15 Jun 2026
Clene (CLNN) grants CFO 15,000 stock options at $5.53 strike - Stock Titan
Thu, 04 Jun 2026
Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 1.05e+007 (%) |
| Held by Institutions | 17 (%) |
| Shares Short | 875 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.962e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -13 % |
| Return on Assets (ttm) | 740 % |
| Return on Equity (ttm) | -56.1 % |
| Qtrly Rev. Growth | 134000 % |
| Gross Profit (p.s.) | -88.59 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 120652 |
| Qtrly Earnings Growth | -3.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.46 |
| Dividend | 0 |
| Forward Dividend | 1.13e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|